drugset / Trial / NCT04926753
Induction Chemotherapy Combined With Toripalimab in Locoregionally-Advanced Laryngo-Hypopharyngeal Squamous Cell Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a non-randomized phase 1, open-labeled clinical study, 1-arm, single center, to observe efficacy and safety of chemotherapy plus PD-L1 antibody Toripalimab every 21 days for 2 cycles as induction regimen in locoregionally-advanced laryngo-hypopharyngeal squamous cell cancer patients.
Timeline
- Start
- 2021-06-01
- Primary completion
- 2022-12-01
- Completion
- 2024-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |
| Subject | fluorouracil | Small molecule | 750 mg/m2 | — |